Course, Prognosis, and Management of Psychosis in Parkinson's Disease: Are Current Treatments Really Effective?

ABSTRACT It is essential to recognize and treat psychosis in Parkinson's disease for several reasons. Studies have shown that psychosis in Parkinson's disease patients is a strong risk factor for nursing home placement. Psychosis may be the greatest source of stress for caretakers of Parkinson's patients; it is often persistent, and its presence markedly increases mortality. Treatment of psychotic symptoms should occur only after potential medical and environmental causes of delirium have been eliminated or addressed. Initial pharmacologic changes should include limiting the patient's antiparkinsonian medications to those that are necessary to preserve motor function. Should that fail, an atypical antipsychotic is presently the treatment of choice. An emerging treatment option is acetylcholinesterase inhibitors. This article reviews what is currently known about the course, prognosis, and treatment strategies in Parkinson's disease psychosis.

[1]  S. Leurgans,et al.  Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease , 1999, Movement disorders : official journal of the Movement Disorder Society.

[2]  G. Stebbins,et al.  Mortality and hallucinations in nursing home patients with advanced Parkinson's disease , 1995, Neurology.

[3]  J. Friedman,et al.  The Role of Atypical Antipsychotics in the Treatment of Movement Disorders , 1999 .

[4]  M. Okun,et al.  Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[5]  Pierre N Tariot,et al.  Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment , 2006, Neurology.

[6]  R. Monastero,et al.  Visual hallucinations and agitation in Alzheimer’s disease due to memantine: report of three cases , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[7]  J. Friedman,et al.  Open‐label flexible‐dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[8]  Roy W Jones,et al.  Memantine in Moderate to Severe Alzheimer’s Disease: a Meta-Analysis of Randomised Clinical Trials , 2007, Dementia and Geriatric Cognitive Disorders.

[9]  J. Friedman,et al.  Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease , 2002, Biological Psychiatry.

[10]  J. Friedman,et al.  Long‐term outcome of clozapine use for psychosis in parkinsonian patients , 2004, Movement disorders : official journal of the Movement Disorder Society.

[11]  A. Crawley,et al.  Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[12]  S. Lipton.  Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond , 2006, Nature Reviews Drug Discovery.

[13]  Lon S Schneider,et al.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. , 2005, JAMA.

[14]  J. Ramírez-Bermúdez,et al.  Aripiprazole in psychosis associated with Parkinson's disease. , 2005, The Journal of neuropsychiatry and clinical neurosciences.

[15]  J. Friedman,et al.  Drug-Induced Psychosis in Parkinson Disease: Phenomenology and Correlations Among Psychosis Rating Instruments , 2005, Clinical neuropharmacology.

[16]  D. Aarsland,et al.  Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia , 2003, International journal of geriatric psychiatry.

[17]  M. Hutchinson,et al.  Cholinesterase inhibition in Parkinson's disease. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[18]  C. Schönfeldt-Lecuona,et al.  Ziprasidone in Parkinson's Disease Psychosis , 2004, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[19]  J. Sanchez-Ramos,et al.  Visual hallucinations associated with Parkinson disease. , 1996, Archives of neurology.

[20]  M. Ceccaldi,et al.  Nonmotor fluctuations in Parkinson’s disease: Frequent and disabling , 2002, Neurology.

[21]  J. Friedman,et al.  Treatment of Psychosis in Parkinson’s Disease , 2003, Drug safety.

[22]  P J Feustel,et al.  Longitudinal outcome of Parkinson’s disease patients with psychosis , 2003, Neurology.

[23]  R. Barker,et al.  The heterogeneity of idiopathic Parkinson's disease , 2002, Journal of Neurology.

[24]  H. Morris,et al.  Aripiprazole associated with severe exacerbation of Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[25]  S. Leurgans,et al.  The malignant course of "benign hallucinations" in Parkinson disease. , 2006, Archives of neurology.

[26]  J. Mellers,et al.  Psychosis in Parkinson’s disease: ‘between a rock and a hard place’ , 2000 .

[27]  W. Oertel,et al.  Ondansetron Treatment of L-dopa-induced Psychosis , 1996, Neurology.

[28]  E. Tolosa,et al.  Cognitive Changes in Parkinson’s Disease Patients with Visual Hallucinations , 2007, Dementia and Geriatric Cognitive Disorders.

[29]  Kiyoharu Inoue,et al.  The Beneficial Effect of Donepezil on Visual Hallucinations in Three Patients with Parkinson's Disease , 2003, Journal of geriatric psychiatry and neurology.

[30]  J. Friedman,et al.  Risperidone and parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[31]  H. Duggal,et al.  Pisa syndrome and atypical antipsychotics. , 2004, The American journal of psychiatry.

[32]  C. Goetz,et al.  Pharmacology of hallucinations induced by long-term drug therapy. , 1982, The American journal of psychiatry.

[33]  Brown Tm,et al.  Clozapine in drug-induced psychosis in Parkinson's disease , 1999, The Lancet.

[34]  S. Factor,et al.  The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia , 2002, Movement disorders : official journal of the Movement Disorder Society.

[35]  M. Rossor,et al.  Delusions and hallucinations in dementia with Lewy bodies: Worsening with memantine , 2005, Neurology.

[36]  D. Aarsland,et al.  Mental symptoms in Parkinson's disease are important contributors to caregiver distress , 1999, International journal of geriatric psychiatry.

[37]  C. d’Souza,et al.  MANAGEMENT OF PSYCHOSIS IN PARKINSON'S DISEASE , 2003, International journal of clinical practice.

[38]  P. Weiden,et al.  Best clinical practice with ziprasidone: update after one year of experience. , 2002, Journal of psychiatric practice.

[39]  R. Rodnitzky,et al.  Predictors of weight loss in Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[40]  G. Stebbins,et al.  Risk factors for nursing home placement in advanced Parkinson's disease , 1993, Neurology.

[41]  Jacob Gordon,et al.  Clozapine in Parkinson's Disease Psychosis: 5-Year Follow-up Review , 2003, Clinical neuropharmacology.

[42]  E. Melamed,et al.  Psychosis in advanced Parkinson's disease , 1995, Neurology.

[43]  J. Friedman,et al.  THE NONMOTOR PROBLEMS OF PARKINSON'S DISEASE , 2000 .

[44]  J. Friedman,et al.  Aripiprazole for Drug-Induced Psychosis in Parkinson Disease: Preliminary Experience , 2004, Clinical neuropharmacology.

[45]  S. Stahl.  Is psychopharmacologic "inoculation" effective in preventing posttraumatic stress disorder? , 2005, The Journal of clinical psychiatry.

[46]  S. Leurgans,et al.  Prospective longitudinal assessment of hallucinations in Parkinson’s disease , 2001, Neurology.

[47]  N. Leopold.  Risperidone treatment of drug‐related psychosis in patients with parkinsonism , 2000, Movement disorders : official journal of the Movement Disorder Society.

[48]  A. Glassman.  Schizophrenia, antipsychotic drugs, and cardiovascular disease. , 2005, The Journal of clinical psychiatry.

[49]  C. Tanner,et al.  Early dopaminergic drug-induced hallucinations in parkinsonian patients , 1998, Neurology.

[50]  W. Ondo,et al.  Double‐blind, placebo‐controlled, unforced titration parallel trial of quetiapine for dopaminergic‐induced hallucinations in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[51]  I. McKeith,et al.  Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[52]  J. Friedman,et al.  Atypical antipsychotics in the treatment of drug‐induced psychosis in Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[53]  J. Kornhuber,et al.  Memantine in moderate-to-severe Alzheimer's disease. , 2003, The New England journal of medicine.

[54]  A. Destée,et al.  Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[55]  E. Sofić,et al.  Serum prolactin, leptin, lipids and lipoproteins levels during antipsychotics treatment in Parkinson's disease and related psychosis. , 2006, Medicinski arhiv.

[56]  A. Gelenberg.  Hats Off to the Reviewers!: (Editorial) , 1998 .

[57]  N. Moore,et al.  The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. , 1992, The Journal of pharmacology and experimental therapeutics.

[58]  M. Oechsner,et al.  Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease? , 2005, Human psychopharmacology.

[59]  I. Shiah,et al.  Ziprasidone in the treatment of Parkinson’s disease psychosis , 2006, European Psychiatry.

[60]  Erwan Bezard,et al.  Novel pharmacological targets for the treatment of Parkinson's disease , 2006, Nature Reviews Drug Discovery.

[61]  B. Ott,et al.  Exacerbation of parkinsonism by tacrine. , 1992, Clinical neuropharmacology.

[62]  J. Jankovic,et al.  Olanzapine treatment for dopaminergic‐induced hallucinations , 2002, Movement disorders : official journal of the Movement Disorder Society.

[63]  S. Lipton.  The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. , 2005, Current Alzheimer research.

[64]  D. Aarsland,et al.  Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study , 2002, Journal of neurology, neurosurgery, and psychiatry.

[65]  M. Kunik,et al.  The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. , 1997, The Journal of neuropsychiatry and clinical neurosciences.

[66]  Joseph Friedman,et al.  Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease , 1998, Neurology.

[67]  R. Sleeper.  Antipsychotic Dose-Sparing Effect with Addition of Memantine , 2005, The Annals of pharmacotherapy.

[68]  A. Fitton,et al.  Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. , 1994, Drugs.

[69]  G. Stebbins,et al.  Hallucinations and sleep disorders in PD , 2005, Neurology.

[70]  J. Friedman,et al.  Diabetes mellitus among parkinsonian patients treated chronically with clozapine. , 2004, Parkinsonism & related disorders.

[71]  H. Frieling,et al.  Treating dopamimetic psychosis in Parkinson's disease: Structured review and meta-analysis , 2007, European Neuropsychopharmacology.

[72]  J. Zarranz,et al.  Use of Ziprasidone in Parkinsonian Patients With Psychosis , 2005, Clinical neuropharmacology.

[73]  A. Alessandri,et al.  Risperidone in levodopa‐induced psychosis in advanced parkinson's disease: An open‐label, long‐term study , 1997, Movement disorders : official journal of the Movement Disorder Society.

[74]  P. D. De Deyn,et al.  Risperidone in the treatment of dopamine‐induced psychosis in Parkinson's disease: An open pilot trial , 2000, Movement disorders : official journal of the Movement Disorder Society.

[75]  J. Schein,et al.  Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. , 1998, The Journal of clinical psychiatry.

[76]  S. Gauthier,et al.  Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies , 2005, International journal of geriatric psychiatry.

[77]  Fabrizio Stocchi,et al.  Factors impacting on quality of life in Parkinson's disease: Results from an international survey , 2002, Movement disorders : official journal of the Movement Disorder Society.

[78]  I G McKeith,et al.  Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial , 2001, Movement disorders : official journal of the Movement Disorder Society.

[79]  H. Klawans,et al.  Levodopa-induced psychosis: a kindling phenomenon. , 1978, The American journal of psychiatry.

[80]  Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. , 1999, The New England journal of medicine.

[81]  J. Growdon,et al.  Clozapine and risperidone treatment of psychosis in Parkinson's disease. , 2000, The Journal of neuropsychiatry and clinical neurosciences.

[82]  D. Aarsland,et al.  Predictors of Nursing Home Placement in Parkinson's Disease: A Population‐Based, Prospective Study , 2000, Journal of the American Geriatrics Society.

[83]  J. Friedman,et al.  Long‐term outcome of quetiapine use for psychosis among parkinsonian patients , 2003, Movement disorders : official journal of the Movement Disorder Society.

[84]  R. Marconi,et al.  Quetiapine and Clozapine in Parkinsonian Patients With Dopaminergic Psychosis , 2004, Clinical neuropharmacology.

[85]  E. Melamed,et al.  Ondansetron for hallucinosis in advanced Parkinson's disease , 1993, The Lancet.

[86]  C. Schönfeldt-Lecuona,et al.  Aripiprazole and Parkinson's disease psychosis. , 2004, The American journal of psychiatry.

[87]  S. Leucht.  Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. , 2001, Neurology.

[88]  M. Hely,et al.  Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years , 2005, Movement disorders : official journal of the Movement Disorder Society.

[89]  K. Chaudhuri,et al.  Non-motor symptoms of Parkinson's disease: diagnosis and management , 2006, The Lancet Neurology.

[90]  V. Lerner,et al.  Successful Use of Donepezil for the Treatment of Psychotic Symptoms in Patients With Parkinson's Disease , 2002, Clinical neuropharmacology.

[91]  G. Lenzi,et al.  Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease , 2002, Neurological Sciences.